MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...
MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...
A high-level overview of MS Emerging Markets Debt Fund (MSD). Stay up to date on the latest price, chart, news, analysis, fundamentals, trading and investment tools.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback